News
BFRI
0.7800
-3.74%
-0.0303
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 1d ago
Biofrontera Reports Positive Phase 3 Ameluz PDT Results
TipRanks · 1d ago
Biofrontera announces positive Phase 3 results for Ameluz PDT
TipRanks · 1d ago
Biofrontera Announces Results From 172 Participants In Its Phase 3 Cliical Study Of Ameluz Photodynamic Therapy To Treat Actinic Keratoses
Benzinga · 1d ago
Biofrontera Reports Positive Phase 3 Results for Ameluz PDT in Treating Actinic Keratoses Beyond Face and Scalp
Reuters · 1d ago
Biofrontera meldet erfolgreiche Phase-3-Studie für Ameluz bei aktinischer Keratose an Extremitäten, Hals und Rumpf
Reuters · 1d ago
BIOFRONTERA INC - TO SUBMIT SNDA TO FDA IN Q3 2026
Reuters · 1d ago
Weekly Report: what happened at BFRI last week (0202-0206)?
Weekly Report · 1d ago
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
Barchart · 1d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 02/03 12:05
Weekly Report: what happened at BFRI last week (0126-0130)?
Weekly Report · 02/02 10:37
Weekly Report: what happened at BFRI last week (0119-0123)?
Weekly Report · 01/26 10:37
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 01/22 12:05
Weekly Report: what happened at BFRI last week (0112-0116)?
Weekly Report · 01/19 10:45
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/15 21:05
BIOFRONTERA INC. ANNOUNCES RECORD PRELIMINARY FOURTH QUARTER 2025 REVENUES BETWEEN $17.0 MILLION AND $17.5 MILLION, REPRESENTING APPROXIMATELY 35% YEAR-OVER-YEAR GROWTH
Reuters · 01/13 13:31
Biofrontera Expects Q4 Revenue Between $17M - $17.5M, FY25 Revenue Between $41.5M - $42M
Benzinga · 01/13 13:31
Biofrontera Inc. Projects 2025 Revenue Growth of Up to 13%
Reuters · 01/13 13:31
Biofrontera Inc. Reports Record Preliminary Q4 2025 Revenue of Up to $17.5 Million
Reuters · 01/13 13:30
Weekly Report: what happened at BFRI last week (0105-0109)?
Weekly Report · 01/12 10:43
More
Webull provides a variety of real-time BFRI stock news. You can receive the latest news about Biofrontera Inc through multiple platforms. This information may help you make smarter investment decisions.
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.